Menu

Markets

Research

News

Learn

AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Krystal Biotech, Inc. KRYS

Full chart Compare
Set alert

Price alert · KRYS

All alert types
300.25 USD -10.59 (-3.41%)

At closeNov 6, 2026, 8:11 AM EST

300.00 -0.25 -0.08%

Pre-market · Nov 6, 8:11 AM ET

299.64 Day range 314.24
192.52 52-week range 382.54
YTD
+21.79%
1 year
+50.22%
Market cap
8.90B
Revenue (ttm)
470.02M
Profit margin
47.91%
EPS (ttm)
7.36
Shares out
29.63M
P/E ratio
40.79
Forward P/E
34.02
YTD return
+21.79%
1-year return
+50.22%
Volume
400.88K
Avg volume
278.36K
Open
310.22
Previous close
310.84
Day's range
299.64 – 314.24
52-week range
192.52 – 382.54
Beta
0.65
Analysts
Strong Buy
Price target
388.22 (+29.3%)
Earnings date
Feb 16, 2027
1D5D1M3M6MYTD1Y2Y5YMAX
Full chart

5D -24.94 (-7.67%)

280300320FriMonTueWedThu300.25

Key statistics

Financials
Enterprise value
8.14B
PEG ratio
0.00
Price / sales
19.60
Price / book
6.42
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
30.20%
Free cash flow
221.59M
Total cash
911.85M
Total debt
8.59M
Return on equity
17.50%
Short % of float
16.21%
50-day average
335.72
200-day average
308.70

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 388.22 +29.3% upside
Target (low)
284.00
Target (mean)
388.22
Target (high)
474.00
Ratings (0m) 12 11 buy · 1 hold · 0 sell
  • Strong buy1
  • Buy10
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Feb 16, 2027

Expected Feb 16, 2027. Consensus EPS estimate 2.30.

Earnings history

Financials — quick view

All financials
KRYS Revenue — quarterly 127.34M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
KRYS Net income — quarterly 63.07M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
KRYS EPS — quarterly 2.13
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

KRYS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 16, 2027Dec 30, 20262.05———
Nov 2, 2026Sep 30, 20261.792.05+0.26+14.53%
Aug 3, 2026Jun 30, 20261.701.79+0.09+5.29%
May 4, 2026Mar 31, 20261.451.83+0.38+26.21%
Feb 17, 2026Dec 31, 20251.621.70+0.08+4.94%
Nov 3, 2025Sep 30, 20251.122.66+1.54+137.50%

Upgrades / downgrades

KRYS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 3, 2026CitigroupmainBuyBuy
Nov 3, 2026TD CowenmainBuyBuy
Nov 3, 2026RBC CapitalmainOutperformOutperform
Oct 15, 2026HC Wainwright & Co.reitBuyBuy
Sep 21, 2026B of A SecuritiesmainBuyBuy
Aug 14, 2026RBC Capitalinit—Outperform

About Krystal Biotech, Inc.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
krystalbio.com

News

All news

Your note

Sign in to keep a note on KRYS — it syncs with the Stock Master app.

Insider holders

KRYS insider holders
InsiderRelationLatest transactionDateShares held
JANNEY DANIEL SPENCERDirectorSaleFeb 26, 20260
KRISHNAN KRISH SChief Executive OfficerSaleSep 3, 20261,565,250
KRISHNAN SUMA MOfficer, Director and Beneficial OwnerSaleSep 3, 20261,493,160
ROMANO KATHRYNOfficerSaleMar 1, 202622,366
ROSSI DINO ADirectorStock GiftAug 13, 202650,000
THOMAS JOHN CHARLES MICHAELGeneral CounselSaleJun 24, 20260

Institution ownership

KRYS institution ownership
Holder% heldSharesValueReported
FMR, LLC14.91%4,418,1971.37BJun 29, 2026
Blackrock Inc.14.11%4,181,4321.30BJun 29, 2026
Avoro Capital Advisors LLC9.75%2,888,888897.98MJun 29, 2026
Vanguard Portfolio Management LLC5.31%1,574,905489.54MJun 29, 2026
State Street Corporation4.56%1,351,158419.99MJun 29, 2026
Vanguard Capital Management LLC4.19%1,240,567385.62MJun 29, 2026

Fund ownership

KRYS fund ownership
Holder% heldSharesValueReported
Fidelity Select Portfolios-Select Biotechnology Portfolio6.08%1,802,622560.33MAug 30, 2026
iShares Trust-iShares Core S&P Mid-Cap ETF3.20%948,897294.96MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.00%889,548276.51MJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund2.75%816,132253.69MAug 30, 2026
SmallCap World Fund Inc2.54%752,244233.83MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.28%675,066209.84MSep 29, 2026